Literature DB >> 8335988

Effect of immunization of pulmonary clearance of Moraxella catarrhalis in an animal model.

I Maciver1, M Unhanand, G H McCracken, E J Hansen.   

Abstract

A murine model for pulmonary clearance of Moraxella catarrhalis was used to determine whether immunization could enhance clearance of this organism from the lungs. Animals actively immunized with outer membrane vesicles of M. catarrhalis cleared an endobronchial challenge with the homologous strain more quickly than did sham-immunized control animals. Western blot analysis of both this immune mouse serum and rabbit antiserum raised against outer membrane vesicles of M. catarrhalis indicated that antibodies were present to both outer membrane protein and lipooligosaccharide antigens. Passive immunization of mice with the immune rabbit serum resulted in enhanced pulmonary clearance of both homologous and heterologous strains of M. catarrhalis, indicating the involvement of serum antibody in this clearance process and the existence of conserved surface antigens in the two different M. catarrhalis strains. These results suggest that this model system may be useful for the identification of vaccine candidates among the surface antigens of M. catarrhalis.

Entities:  

Mesh:

Year:  1993        PMID: 8335988     DOI: 10.1093/infdis/168.2.469

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review.

Authors:  S Sethi; T F Murphy
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

Review 2.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

3.  Moraxella catarrhalis outer membrane protein CD elicits antibodies that inhibit CD binding to human mucin and enhance pulmonary clearance of M. catarrhalis in a mouse model.

Authors:  Dai-Fang Liu; John C McMichael; Steven M Baker
Journal:  Infect Immun       Date:  2007-04-02       Impact factor: 3.441

4.  Mapping of a protective epitope of the CopB outer membrane protein of Moraxella catarrhalis.

Authors:  C Aebi; L D Cope; J L Latimer; S E Thomas; C A Slaughter; G H McCracken; E J Hansen
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

5.  Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization.

Authors:  D Chen; J C McMichael; K R VanDerMeid; D Hahn; T Mininni; J Cowell; J Eldridge
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

6.  Immune response to an 18-kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate.

Authors:  J Keenan; J Oliaro; N Domigan; H Potter; G Aitken; R Allardyce; J Roake
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

Review 7.  Branhamella catarrhalis: epidemiology, surface antigenic structure, and immune response.

Authors:  T F Murphy
Journal:  Microbiol Rev       Date:  1996-06

8.  Human immune response against outer membrane proteins of Moraxella (Branhamella) catarrhalis determined by immunoblotting and enzyme immunoassay.

Authors:  M E Helminen; R Beach; I Maciver; G Jarosik; E J Hansen; M Leinonen
Journal:  Clin Diagn Lab Immunol       Date:  1995-01

9.  Characterization of proteins Msp22 and Msp75 as vaccine antigens of Moraxella catarrhalis.

Authors:  Elizabeth A Ruckdeschel; Aimee L Brauer; Antoinette Johnson; Timothy F Murphy
Journal:  Vaccine       Date:  2009-09-26       Impact factor: 3.641

10.  Use of the Chinchilla model to evaluate the vaccinogenic potential of the Moraxella catarrhalis filamentous hemagglutinin-like proteins MhaB1 and MhaB2.

Authors:  Teresa L Shaffer; Rachel Balder; Sean W Buskirk; Robert J Hogan; Eric R Lafontaine
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.